Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Onur Baser"'
Publikováno v:
Blood. 132:4770-4770
Background: For decades, CRAB criteria (hypercalcemia, renal impairment, anemia, and bone disease) have been used to diagnose multiple myeloma (MM), but little is known about the economic burden of CRAB in patients with MM who have relapsed. The only
Publikováno v:
Blood. 128:3574-3574
Introduction: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common sub-type of non-Hodgkin lymphoma. Despite advances in immunochemotherapy, a significant portion of individuals with DLBCL are refractory or relapse following initial treatment and
Autor:
Erin R. Weeda, Philip S. Wells, Li Wang, Frank Peacock, Onur Baser, Crivera Crivera, Neela K Kumar, Jeff Schein, Craig I Coleman, Gregory J. Fermann, Christine G. Kohn
Publikováno v:
Blood. 128:533-533
Background: Both the simplified Pulmonary Embolism Severity Index (sPESI) and the multivariable In-hospital Mortality for Pulmonary embolism using Claims daTa (IMPACT) rule classify patients' risk of early post-pulmonary embolism (PE) complications.
Publikováno v:
Blood. 128:5924-5924
Background: Despite an increasing incidence of multiple myeloma (MM) with advancing age and life expectancy, there are few real-world claims-based analyses describing treatment patterns and healthcare costs associated with use of novel treatments.1,2
Publikováno v:
Blood. 128:5952-5952
Background: Despite a relatively higher incidence in the veteran population, there are few real-world claims-based analyses to describe Multiple Myeloma (MM) treatment patterns among this patient population (Landgren O, Blood, 2006). This study aimed
Autor:
Allison Keshishian, Chad Patel, Lin Xie, Kwanza Price, Shalabh Singhal, Jack Mardekian, Prianka Singh, Jeffrey Trocio, Amanda Bruno, Kevin Odell, Wilson Tan, Amin N Alpesh, Lien Vo, Onur Baser
Publikováno v:
Blood. 126:745-745
INTRODUCTION: Recent large randomized controlled trials have shown that novel oral anticoagulants (NOACs) are at least as effective as warfarin for risk reduction of stroke or systemic embolism in patients with non-valvular atrial fibrillation (NVAF)
Autor:
Xianchen Liu, Lin Xie, Onur Baser, Jack Mardekian, Wilson Tan, Eduardo Ramacciotti, Hemant Phatak
Publikováno v:
Blood. 122:2916-2916
Introduction It is crucial to assess clinical benefit and bleeding risk when selecting an anticoagulant for patients with venous thromboembolism (VTE). This study examined the incidence of major bleeding and non-major bleeding and clinical predictors